Though the drug is not available for purchase or prescription yet, medical professionals expect retatrutide to reshape obesity treatment once regulatory approval is complete
The Food and Drug Administration (FDA) has approved three GLP-1s for obesity-related treatment, including Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide)
But the study had significant flaws
Eyer F, Felgenhauer N, Gempel K, Steimer W, Gerbitz KD, Zilker T
Both HRS-9531 and MET-097 I think have a chance to help break the duopoly into smaller pieces, but itll still take until probably 2027 at the absolute earliest to see this happen and even then itll be a drug not featured during this conference
soil Sci